Stock Evaluator: Sartorius Stedim Biotech S.A. (SRTOY)
Sartorius Stedim Biotech S.A. SRTOY
$19.16
-0.25
-1.28%
July 31, 2026 3:47:43 PM
EST
Volume: 10,551
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
| DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Financial Summary
| Share Statistics | SRTOY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $18,951.2 | $1,774.7 | 85% |
|
| Shares Out (Mil) | 110.7 | 94.8 | 64% |
|
| Institutional Ownership | 50.0% | 90.1% | 30% |
|
| Float (Mil) | 27.7 | 69.9 | 35% |
|
| Beta | 1.15 | 1.20 | 68% |
|
| Avg Daily Volume (000s) | 33 | 838 | 24% |
|
| Price Change (52-week) |
(0.5%) | 81.0% | 45% |
|
| Growth | SRTOY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.3% | 7.8% | 52% |
|
| Net Income (5yr) | (5.4%) | (13.7%) | 33% |
|
| EPS (5yr) | (6.4%) | 0.7% | 24 |
|
| Dividends (5yr) | (0.5%) | 0.0% | 75% |
|
| Cash Flow (5yr) | (57.4%) | (15.0%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SRTOY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,433 | $763 | 69% |
|
| Net Income (TTM) (Mil) | $334 | ($14) | 74% |
|
| EPS (TTM) | $3.439 | ($0.200) | 81% |
|
| Operating Cash Flow (TTM) (Mil) | $901 | $53 | 79% |
|
| Net Cash Flow (TTM) (Mil) | ($19) | ($5) | 26% |
|
| Long-Term Debt (Q1) (Mil) | $2,385 | $270 | 77% |
|
| Enterprise Value (Q1) (Mil) | $20,753 | $2,430 | 84% |
|
| Valuation | SRTOY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 3.00 | na |
|
| P/E | na | 43.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | SRTOY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 44.9% | 47.6% | 56% |
|
| Net Margin | 9.7% | (2.9%) | 62% |
|
| ROA | 3.8% | (3.2%) | 66% |
|
| ROE | 7.4% | (4.5%) | 50% |
|
| Liabilities to Assets | 46.4% | 43.0% | 38% |
|
| F-Score | na | 5 | na |
|
Sartorius Stedim Biotech S.A. did not pass any screens on 7/30/2026.
